Personality
7
Open
7
Cons
4
Extr
5
Agre
4
Neur
SPARC
Healthcare · Small Cap
High Growth · Innovation-Led
About
Anilkumar Raghavan is the Chief Executive Officer of SPARC, a Small Cap company in the Healthcare sector with a market cap of ₹4K Cr. A Pragmatic leader with 30 years of experience, he is known for consensus-driven decision-making and partnership seeker strategy. Oversees a research-driven organizational strategy focused on new drug delivery systems within a highly regulated pharma framework.
FAQ
What is Anilkumar Raghavan's leadership style?
Anilkumar Raghavan is classified as a Pragmatic leader. He is consensus-driven in decision-making, with a category creator motivation and steady-marathon pace of execution.
What is Anilkumar Raghavan's educational background?
Anilkumar Raghavan holds a B.Tech (Industrial Engineering) from CET Trivandrum (Univ of Kerala) and a M.E..
Who is the CEO of SPARC?
Anilkumar Raghavan is the Chief Executive Officer of SPARC. He has been with the company for 11 years and in the current role for 11 years.
Leadership DNA
ArchetypePragmatic
MotivationCategory Creator
CrisisSteady Hand
DecisionConsensus-Driven
GrowthPartnership Seeker
PeopleInstitution Builder
InnovationDisruptor
PaceSteady-Marathon
PurposeMission-First
CustomerB2B-Enterprise
EmployerLearning Ground
BrandTechnical-Expert
FocusProduct Innovation
OrientationDeep Specialist
Leadership Evidence
“Oversees a research-driven organizational strategy focused on new drug delivery systems within a highly regulated pharma framework.”
⚡ Crisis●●●●○
As CEO of SPARC, he has maintained a consistent focus on R&D and long-term product development cycles despite the inherent volatility and regulatory pressures of the specialty pharma sector.
🎯 Motivation●●●●○
SPARC's business model is explicitly built around creating novel chemical entities and differentiated formulations rather than competing purely on generic volume.
👥 People●●●○○
His leadership style emphasizes consensus and the development of specialized scientific talent required to sustain a research-driven pharmaceutical pipeline.
📈 Growth●●●●○
SPARC's growth strategy relies heavily on licensing out its novel drug candidates to global pharmaceutical partners for commercialization.
💡 Innovation●●●●○
As a dedicated R&D spin-off of Sun Pharma, SPARC focuses exclusively on developing New Chemical Entities (NCEs) and novel drug delivery systems rather than generic manufacturing.
🏃 Pace●●●●○
Drug discovery and clinical trials are inherently long-term, multi-year processes that require methodical, patient capital rather than rapid-fire product launches.
🌱 Purpose●●●○○
The company's institutional mandate is the discovery of breakthrough therapies for unmet medical needs, placing scientific advancement at the core of its existence.
🏷️ Brand●●●●●
Its market identity is defined entirely by its specialized capability in complex molecular research and proprietary drug delivery platforms.
🤝 Customer●●●●●
SPARC operates on a licensing and partnership model, selling its intellectual property and drug candidates to global pharmaceutical enterprises rather than direct-to-consumer.
💼 Employer●●●○○
The company serves as a specialized hub for scientists and researchers seeking deep exposure to advanced drug discovery, often acting as a career incubator for highly technical talent.
📋 Mandate
Success depends on long-term R&D breakthroughs and bringing a strong pipeline of specialty pharmaceutical products to market.
🏢 Culture●●●○○
Specialized drug research company focused on R&D where scientific outcome is the primary KPI.
Financials
Revenue FY25₹72 Cr
PAT FY25₹-3425094000
Rev CAGR 5Y-19.4%
OPM-465.5%
NPM-477.3%
ROE157.9%
ROCE863.1%
P/E—
Fwd P/E2.1
P/B-11
D/E—
Promoter73%
Institutional2.6%
Mkt Cap₹4K Cr
Compensation
To Be Published
Data being verified from audited reports
